Increasing digitalization is anticipated to propel growth of the global connected drug delivery devices market. Fortune Business Insights has recently announced a report, titled “Connected Drug Delivery Devices Market Size, Share and Global Trend By Product Type (Sensors, Integrated devices), Application (Diabetes, Multiple Sclerosis, Asthma and COPD, Hypertension), End Users (Home Care Settings, Hospitals, Surgical Centers) and Geography Forecast till 2026” to study various factors influencing the market’s trajectory. The increasing adoption of mobile apps for medical purposes is expected to increase the growth rate in the market.
For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/connected-drug-delivery-devices-market-100380
By Product Type
· Integrated devices
· Multiple Sclerosis
· Asthma and COPD
By End User
· Home Care Settings
· Surgical Centers
· North America (USA and Canada)
· Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
· Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
· Latin America (Brazil, Mexico and Rest of Latin America)
· Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
AptarGroup, Inc., and Propeller Health Sets Higher Standards for Other Players
The U.S. Food and Drug Administration approved AliveCor, Inc.’s new product, KardiaBand. The devices are enabled with personal electrocardiogram, to detect sinus heart rhythms and atrial fibrillation. Development of new devices is further expected to increase growth potential of the global connected drug delivery devices market.